On or around 12/01/2017 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: September 13, 2017
According to the Complaint, on August 1, 2017, PharMerica’s Board of Directors (the “Board” or “Individual Defendants”) caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”) with affiliates of Kohlberg Kravis Roberts & Co. L.P.
On September 6, 2017, in order to convince PharMerica shareholders to vote in favor of the Proposed Merger, the Complaint alleges the Board authorized the filing of a materially incomplete and misleading Preliminary Proxy Statement on a Schedule 14A (the “Proxy”) with the Securities and Exchange Commission (“SEC”), in violation of Sections 14(a) and 20(a) of the Exchange Act.
This case was voluntarily dismissed as moot on December 1, 2017.
Company & Securities Information
Defendant: PharMerica Corporation
Industry: Medical Equipment & Supplies
Headquarters: United States
Ticker Symbol: PMC
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Rodney Martin, et al. v. PharMerica Corporation, et al.